NCT06567743Phase 2Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Study sponsor: CG Oncology, Inc. · CGON

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03-31Estimated
Enrollment · participants325Estimated
Source updated2026-09-03Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview